Skip Navigation LinksHome > March 2008 - Volume 3 - Issue 3 > State of the Journal
Text sizing:
A
A
A
Journal of Thoracic Oncology:
doi: 10.1097/JTO.0b013e318166624a
Editorial

State of the Journal

Jett, James R. MD

Free Access
Article Outline
Collapse Box

Author Information

From the Division of Pulmonary Medicine and Medical Oncology, Mayo Clinic, Rochester, MN.

Disclosure: The author is the editor of Journal of Thoracic Oncology, but otherwise has no conflict of interest to report.

Address for correspondence: James R. Jett, Mayo Clinic, 200 First St. S.W. Rochester, MN 55905. E-mail: jett.james@mayo.edu

2007 is now history; it was an excellent year for the Journal of Thoracic Oncology (JTO). I want to start by thanking the many reviewers who have volunteered their time and effort to help improve the quality of the published manuscripts. Following this editorial is a list of those who participated in JTO manuscript reviews in 2006 and 2007. On average, each person on the list has participated in two reviews, but many of these individuals have done 10 or more. On behalf of the associate editors and editorial staff, we sincerely THANK YOU!!

Total manuscript submissions have experienced a huge increase, from 250 in 2006 to nearly 450 in 2007. Along with the increased numbers, there has been continued improvement in the quality of submissions, allowing the associate editors to be more selective in what we deliver to our membership and readers. Overall, the time from manuscript submission to first decision is 23.5 days (32 days for original articles only). The majority of JTO reviewers are completing their review within the requested 2 weeks and approximately 85% are completed within 3 weeks. The challenge is still with that final 15% of late reviews. We will work hard to decrease the late reviews as we know that timely decisions are a priority for our authors.

The geographic locations from which manuscripts were submitted in 2007 were as follows: Europe (Eastern and Western) (33%), Asia/Australia (29%), North American (33%), and the rest of the world (4%). Especially encouraging was the fact that we received manuscripts from a number of countries for the first time.

The International Association for the Study of Lung Cancer (IASLC) Staging Committee published six landmark papers in JTO in 2007, including the proposed new international staging system for non-small cell lung cancer.1–6 The new IASLC Staging System is working its way through the International Union Against Cancer and the American Joint Committee on Cancer approval processes and it is anticipated that it will be adopted officially (with minimal change) in January 2009.5

Other highlights of the year include the publication and distribution in Spain of three Spanish language issues of JTO. These were selected from the English language version under the direction of Dr. Ramon Rami-Porta, Editor of the Spanish edition. Our thanks to Dr. Rami-Porta for his dedication and making the Spanish edition of JTO a reality. In 2008, an additional 2800 Spanish language JTO copies will be distributed to physicians and scientists in Mexico and South America. We hope that this dissemination of information will increase membership and participation in IASLC by physicians and scientists from those countries.

In December 2007, the first issue of a Japanese language version of JTO was published. The editors of the Japanese language JTO are Drs. Nagahiro Saijo, Harubumi Kato, and Ryosuke Tsuchiya. It is anticipated that there will be four Japanese language issues per year. Each issue contains two full article and four abstract article translations selected by the editors from the English language version. Congratulations to our Japanese editors for their efforts in bringing this project to fruition.

The first 2 years for our new journal have gone exceptionally well. There have been many successes (and only a few glitches)—the reasons are myriad. First, has been the tremendous support by you, the members of IASLC. Our publisher, Lippincott-Williams-and-Wilkins and David Myers, in particular, have been outstanding in delivering everything agreed to and more. The JTO managing editor, Mary Sharkey, has been superb. She is amazing at keeping the process of publication on track and at fixing any problem that arises. The associate editors, a veritable list of Who's Who in Lung Cancer, have given a tremendous amount of time and effort to making the JTO a first rate journal. My sincere thanks to each of you for these efforts.

Our plans for 2008 are to continue to improve. We anticipate a further rise in the number of manuscript submissions and we will strive to shorten the time to first decision. We hope to eliminate the number of reviews that take more than 2 months. We are planning to increase the number of “State-of-the-Art: Concise Review” articles. We will continue our efforts in “Pathway of the Month” articles to help keep us informed on the rapidly changing basic science areas. Finally, under the leadership of Dr. John Crowley, the statistical editor of JTO, we are planning to launch a series of articles on statistics and clinical trial design. These will be delivered in useful portions, much like the pathway articles.

Remember, this is your JTO. If you have ideas that you think would enhance the journal, please share your ideas with us. If there are things that you think we are doing wrong, or could do better, please let us know. As an editor, I am open to new ideas and would welcome your comments and suggestions. Our goal is to deliver to you, the membership, the highest quality journal possible.

Back to Top | Article Outline

REFERENCES

1. Rami-Porta R, Ball D, Crowley J, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2007;2:593–602.

2. Rusch VW, Crowley J, Giroux DJ, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol 2007;2:603–612.

3. Postmus PE, Brambilla E, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the Revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancer. J Thorac Oncol 2007;2:686–693.

4. Groome PA, Bolejack V, Crowley JJ, et al. The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007;2:694–705.

5. Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007;2:706–714.

6. Shepherd FA, Crowley J, Van Houtte P, et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. J Thorac Oncol 2007;2:1067–1077.

© 2008International Association for the Study of Lung Cancer

Login

Article Tools

Share

Other Ways to Connect

Twitter
twitter.com/JTOonline

 



Visit JTO.org on your smartphone. Scan this code (QR reader app required) with your phone and be taken directly to the site.

 For additional oncology content, visit LWW Oncology Journals on Facebook.